Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020023560 - ISOQUINOLINE COMPOUNDS AND USES THEREOF

Publication Number WO/2020/023560
Publication Date 30.01.2020
International Application No. PCT/US2019/043123
International Filing Date 23.07.2019
IPC
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 401/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 403/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14containing three or more hetero rings
C07D 405/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
CPC
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07D 401/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
C07D 403/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
02containing two hetero rings
12linked by a chain containing hetero atoms as chain links
C07D 403/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
403Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
14containing three or more hetero rings
C07D 405/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
405Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
14containing three or more hetero rings
Applicants
  • F. HOFFMANN-LA ROCHE AG (AllExceptUS)
  • GENENTECH, INC. [US]/[US] (US)
Inventors
  • LIANG, Jun
  • MALHOTRA, Sushant
  • MENDONCA, Rohan V.
  • RAJAPAKSA, Naomi
  • SIU, Michael
  • STIVALA, Craig
  • TELLIS, John C.
  • WEI, BinQing
  • CHAN, Bryan K.
  • DROBNICK, Joy Alison
  • GAZZARD, Lewis J.
  • HEFFRON, Timothy
  • JONES, Graham
  • LAINCHBURY, Michael
  • MADIN, Andrew
  • SEWARD, Eileen Mary
  • CARTWRIGHT, Matthew W.
  • GANCIA, Emanuela
  • FAVOR, David
  • FONG, Kin Chiu
  • GOOD, Andrew
  • HU, Yonghan
Agents
  • TIAN, Zongqiang Bill
  • AUMAIS, Jonathan
  • BONE, Richard G.A.
  • BUCKWALTER, Brian L.
  • CHANG, Y. Elaine
  • CHI, I. Shannon
  • CLARK, Kevin M.
  • COBURN, Cara M.
  • COLANTONIO, Jessica R.
  • CRISSEY, Todd M.
  • CUI, Steven
  • DAVIS, Bradley E.
  • DAVIS, Jennifer L.
  • DREGER, Ginger
  • FANG, Carol A.
  • GHOSE, Shameek
  • HALL, Robert C.
  • HARLOCKER, Susan
  • HEIDER, Julie A.
  • HESSLER, Amy
  • HILL, Laurie L.
  • JOHNSTON, Sean A.
  • KAFKA, Mark D.
  • KAIS, Samuel
  • KALINOWSKI, Grant E.
  • KRAMMER, Andre
  • LEE, Michelle
  • LEE, Wendy M.
  • LI, Qianru
  • MACKENZIE, Katherine J.
  • MCCLELLAN, Kelly B.
  • REDDY, Daphne
  • ROPP, Traci H.
  • SCHWARTZ, Timothy R.
  • SCOTT, Derek B.
  • SHERMAN, Daniel E.
  • SCHOLTZ, Charles K.
  • SHU, Cindy
  • TAN, Anna M.
  • WAIS, Rebecca J.
  • WHITEHEAD, Andrew P.
  • WONG, Charles C.
Priority Data
PCT/CN2018/09678024.07.2018CN
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ISOQUINOLINE COMPOUNDS AND USES THEREOF
(FR) COMPOSÉS D'ISOQUINOLINE ET LEURS UTILISATIONS
Abstract
(EN)
Isoquinoline compounds of formula (I) variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
(FR)
L'invention concerne des composés d'isoquinoléine de formule (I) et leur utilisation en tant qu'inhibiteurs de HPK1 (kinase hématopoïétique 1). Les composés de l'invention sont utiles dans le traitement de troubles dépendant de HPK1 et pour l'amélioration d'une réponse immunitaire. L'invention concerne également des procédés d'inhibition de HPK1, des méthodes de traitement de troubles dépendant de HPK1, des procédés d'amélioration d'une réponse immunitaire, et des procédés de préparation des composés d'isoquinoline.
Also published as
JP2021503147
Latest bibliographic data on file with the International Bureau